Snappy Kraken Unveils End-to-End Lead Conversion for Financial Advisors; Appoints Cheryl Nash to Board
ORMOND BEACH, Fla.--(BUSINESS WIRE)-- Snappy Kraken, the martech innovator powering simpler, smarter advisor marketing, today announced the launch of its Smart Growth Suite, a complete system that automates lead conversion for enterprise firms, mid-market organizations and individual advisors. The Smart Growth Suite replaces fragmented tech stacks with a unified system for automated, targeted marketing and lead conversion.
As part of the suite, Snappy Kraken is introducing Dynamic Groups, a capability designed to help advisors automate segmentation and support personalized outreach to convert leads efficiently. With Dynamic Groups, advisors can segment contacts using attributes like age, gender, investable assets and more, enabling personalized messaging without manual work. Dynamic Groups helps advisors deliver timely, relevant messages to specific audiences—whether following up with referrals, re-engaging cold leads or reaching high-value clients.
'Individual advisors are constantly challenged to compete with larger firms that have more resources to invest in marketing technology,' said Robert Sofia, founder and CEO of Snappy Kraken. 'Our Smart Growth Suite levels the playing field—equipping firms and advisors with intelligent automation, always-on segmentation and powerful analytics—all without the heavy lift. Dynamic Groups also puts real-time intelligence behind every campaign, eliminating static lists and busywork in prospecting. It's segmentation that adapts as fast as advisors' clients do.'
The Smart Growth Suite combines tools typically spread across CRMs, marketing automation platforms, content hubs and AI tools—offering a compliant, ready-to-use system that automates workflows across the lead-to-client lifecycle with powerful admin-level control for larger firms. Based on Snappy Kraken's performance data, firms using the suite see a 20% to 340% increase in lead conversion rates, driven by automated lead generation sequences. In addition to the segmentation capabilities of Dynamic Groups, key features of the suite include:
Automation: Automatically capture, enrich and route leads based on behavior and profile with AI-powered lead capture technology. Advisors can assign leads to targeted campaigns without manual effort, enabling them to focus on building clients and prospect relationships while the suite manages the core lead generation process.
Content: Deliver multi-channel communications through web, email, text and video, designed to guide prospects through the path to become a client with consistent, personalized messaging.
Insights: Gain visibility into campaign effectiveness with real-time reporting on performance, lead engagement and pipeline health—across individual advisors or an enterprise firm.
Integrations: Activate integrations that automatically enrich lead data. Advisors can utilize integrations that deliver AI-powered insights to enrich prospect data, identify high-potential leads, assess financial capacity and launch personalized marketing campaigns.
In addition to the Smart Growth Suite, Snappy Kraken also announced the appointment of Cheryl Nash, President, APL of InvestCloud, as a board member. With more than 30 years of experience in wealth management and financial technology, Nash's appointment will serve as an asset as Snappy Kraken continues to enhance its marketing technology solutions. Her appointment further strengthens Snappy Kraken's focus on driving organic growth for enterprises and advisors, reinforcing its capabilities in lead capture, contact management and nurturing strategies.
'I'm honored to join the Snappy Kraken board and support a team that's redefining how advisors connect with clients through technology,' said Nash. 'For advisors focused on accelerating organic growth, Snappy Kraken's innovative, tech-driven approach to personalized marketing can help deepen relationships and create lasting engagement.'
Snappy Kraken will announce Nash's appointment and present the full lead conversion system at the Jolt! Conference, taking place June 9–11, 2025 in Nashville, Tennessee. Advisors and firm leaders will see the platform in action and gain insights on effective implementation.
To request a demo of the Smart Growth Suite, please visit snappykraken.com/growth-suite-demo. For more information on Snappy Kraken and its tailored solutions for both large enterprises and smaller RIAs, please visit snappykraken.com.
About Snappy Kraken
Snappy Kraken is an award-winning marketing technology (martech) firm that provides original content, marketing automation, personalized website design and bold, unique marketing campaigns for the financial services industry. Each of these marketing campaigns is informed by rich data.
Snappy Kraken's innovative approach has earned the company widespread recognition. In 2024, Snappy Kraken received the Wealth Management Industry Award (Wealthie) for Digital Campaign of the Year for its Behavior Gap Audience Builder, and in 2023, it won the Wealthie for Thought Leadership for the Jolt! Conference. The company was also awarded Financial Planning's 2024 Innovation Awards for its AI-Powered Email Builder and, for four consecutive years, was named Best Overall Content Marketing Software by MarTech Breakthrough (2019-2023). In recent years, Snappy Kraken also ranked #8 and #3 on Financial Planning's Best Fintechs to Work For lists.
To learn more about Snappy Kraken's solutions for financial advisors, including white-labeled enterprise solutions, and to use the new and enhanced tools recently announced, visit SnappyKraken.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the Company is taking to strengthen the safety profile in non-ambulatory patients. These steps follow a second reported case of acute liver failure (ALF) resulting in death. The cases of ALF to date have both occurred in non-ambulatory individuals with Duchenne. Sarepta extends its deepest sympathies to the affected families and care teams. Key Safety Initiatives Evaluating and Enhancing Immunosuppressive Regimen: As part of a comprehensive review of safety data, Sarepta is taking proactive steps to mitigate the risk of acute liver failure in non-ambulatory patients. Sarepta is working to immediately convene an independent group of leading experts in Duchenne and liver health to consider an enhanced immunosuppression regimen for ELEVIDYS. This panel will evaluate data and assess our proposed regimen, which includes sirolimus and is supported by preclinical data demonstrating the effectiveness of additional immunosuppression in moderating liver enzyme elevations, a key factor in mitigating potential safety events. Sarepta will share the panel's recommendations with the U.S. Food & Drug Administration (FDA), and implementation of any new regimen will be subject to FDA guidance and allowance. Suspending Shipments of ELEVIDYS for Non-Ambulatory Patients: Sarepta is temporarily suspending shipments of ELEVIDYS for non-ambulatory patients while an enhanced immunosuppressive regimen is evaluated, discussed with regulatory bodies, and put in place. For ambulatory patients, no treatment changes are being proposed and the current practice of administering corticosteroids before and after ELEVIDYS infusion, along with post-treatment monitoring, remains the same. ENVISION Study Paused: Sarepta has voluntarily paused dosing in the ENVISION clinical study (also known as Study SRP-9001-303). FDA concurs with this action. The pause will allow for the evaluation of a protocol amendment to incorporate an enhanced immunosuppressive regimen for the non-ambulatory patient cohort and incorporate any additional feedback from the FDA. Regulatory alignment is needed before screening and dosing in ENVISION may resume. ENVISION is a global, randomized, double-blind, placebo-controlled trial evaluating ELEVIDYS in older ambulatory and non-ambulatory individuals living with Duchenne muscular dystrophy. In the U.S., it serves as the confirmatory trial required under the FDA's accelerated approval pathway for non-ambulatory patients. 'Our paramount priority is the safety and well-being of the patients we serve. We are taking immediate, decisive steps to better understand and mitigate the risk of acute liver failure, including enhancing the immunosuppressive regimen, for those with Duchenne who are non-ambulatory,' said Louise Rodino-Klapac, Ph.D., chief scientific officer and head of research & development, Sarepta. 'We are deeply saddened by the loss of a second patient and extend our heartfelt condolences to the patient's family and his care team during this incredibly difficult time. Duchenne muscular dystrophy is a devastating disease that profoundly affects lives and often cuts them far too short. With more than 900 individuals treated to-date, we know how much hope families place in new treatment options like ELEVIDYS – and we are committed to honoring that hope by acting swiftly, guided by scientific rigor and the insights of leading experts, to strengthen safety for all future patients.' Commitment to Long-Term Safety and Understanding Sarepta remains committed to a thorough approach and the highest standards of patient safety and scientific rigor. The event has been reported to FDA and global health authorities and will inform ongoing discussions around a potential label update to reflect the risk of severe ALF and additional immune management strategies for non-ambulatory patients. While elevated liver enzymes are a known class effect of all AAV-based gene therapies, the exact mechanism behind AAV-related liver toxicity remains unclear. Current evidence suggests it is likely driven by an adaptive immune response. The Company will provide additional updates as appropriate. Investor Conference Call Details Sarepta will be hosting a conference call and webcast to discuss this update and provide an update on the Company's business on Monday, June 16, 2025, at 8:00 am Eastern time. The event will be webcast live under the investor relations section of Sarepta's website at: and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials, ELEVIDYS, the potential benefits of an enhanced immunosuppression regimen in dosing in non-ambulatory patients, and expected plans and milestones, including providing additional updates as appropriate and engaging with regulators on an enhanced immunosuppressive regimen for dosing in non-ambulatory patients. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials are positive, these data may not be sufficient to support approval by the FDA or other global regulatory authorities; success in clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or with advisory committee recommendations, or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; we may not be able to comply with all FDA requests in a timely manner or at all; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.
Business Wire
8 hours ago
- Business Wire
FinTech Leader Kennel Connection Launches Enhanced Report Cards to Help Pet Care Pros Save Time and Build Trust
MOORPARK, Calif.--(BUSINESS WIRE)--Kennel Connection, a leader in pet care management software and a 100GROUP company, is proud to announce a comprehensive update to its Report Cards feature, a powerful and modernized communication tool designed to help pet care businesses deliver personalized updates to clients with ease. 'This new version of Report Cards helps businesses deliver meaningful updates without slowing down their day.' — Jeff Brodsly, CEO While report cards have long been part of the Kennel Connection experience, this major overhaul introduces a redesigned interface, enhanced functionality, and new delivery options that make the system more powerful and user-friendly than ever. Built for daycare, boarding, and special services, the revamped Report Cards feature allows pet care facilities to share structured, customized updates via email or SMS in just a few clicks. Staff can quickly add notes about a pet's behavior, eating habits, elimination, and playtime by selecting from pre-written messages or adding their own touch. The addition of optional pet photos brings each update to life, helping clients feel connected to their pet's stay while reinforcing trust in the business. Users can now choose from a variety of sleek, professionally designed templates that reflect the modern pet care experience. Whether you're aiming for playful and colorful or clean and minimalist, there's a layout to match your brand and client preferences, offering both visual polish and practical customization. A Streamlined Workflow with a Personal Touch With Report Cards, pet care teams can create and send professional, mobile-friendly updates directly from the appointment screen, dashboard, pet card, client card, or schedule. Each report card can be sent once for the full stay or as a daily summary, allowing businesses to tailor the frequency and content to their preferred workflow. Key capabilities of the revamped Report Cards feature include: Customizable sections for behavior, meals, elimination, and playtime Flexible messaging options including rotating text templates and editable notes Quick delivery via email or text with the option to include pet photos Preview and edit tools for enhanced control and personalization Multiple clean, modern templates to choose from, allowing alignment with business branding "Client communication is at the heart of any successful pet care operation," said Jeff Brodsly, Owner and CEO of Kennel Connection and 100GROUP. "This new version of Report Cards helps businesses deliver meaningful updates without slowing down their day. It's about giving pet parents peace of mind while making it easier for teams to stay efficient and consistent." Part of a Broader Vision The update of Report Cards aligns with Kennel Connection's ongoing commitment to innovation, efficiency, and customer satisfaction. As part of its growing suite of tools, including integrated credit card processing, digital contracts, advanced booking, and text-to-pay, Report Cards further supports pet care businesses in delivering a seamless and modern client experience. About Kennel Connection: Kennel Connection is a leading provider of innovative software solutions for pet care businesses, offering a comprehensive suite of management tools designed to streamline operations and enhance customer experience. With a focus on empowering pet care professionals, Kennel Connection's feature-rich platform encompasses reservation management, client communication, billing, and reporting, alongside innovative features such as Text-To-Pay, digital contracts, advanced online booking, and integrated credit card processing; all aimed at driving efficiency and organization in day-to-day operations. Kennel Connection leverages cutting-edge technology to deliver tailored solutions that cater to the unique needs of pet care providers nationwide. For more information about Kennel Connection, visit
Business Wire
10 hours ago
- Business Wire
Perma-Pipe International Holdings, Inc.公布2025會計年度第一季財務業績
德州斯普林--(BUSINESS WIRE)--(美國商業資訊)-- Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH)今天公布了截至2025年4月30日的第一季財務業績。 總裁兼執行長Saleh Sagr指出：「第一季銷售額為4670萬美元，較去年同期的3430萬美元成長1240萬美元，增幅36.2%。歸屬於普通股的淨收入為500萬美元，較上年第一季的140萬美元成長360萬美元，增幅達243%。」 Sagr先生繼續說道：「目前未完成訂單為1.311億美元，相較2025年1月31日的1.381億美元減少700萬美元。然而，相較2024年4月30日的6310萬美元，該公司的未完成訂單大幅增加6800萬美元，增幅達108%。我們對現有未完成訂單水準感到鼓舞，其仍為去年第一季末報告之未完成訂單水準的兩倍以上。」 總裁兼執行長Saleh Sagr表示：「第一季業績代表公司實現了前所未見的業務表現，無論是銷售額還是歸屬於普通股的淨收入，均為2017年從MFRI轉變為Perma-Pipe以來第一季的最高水準。此外，第一季歸屬於普通股的淨收入約占公司2024會計年度全年業績的55%。」 Sagr先生評論道：「我們對各市場的業務活動水準感到滿意，這推動了第一財季整體銷售額和收益的成長。此外，美洲和中東及北非(MENA)地區的業績表現令人振奮，兩個地區在第一季取得了不相上下的業績。」 Sagr先生總結道：「公司第一季業績的強勁表現為2025會計年度剩餘季度提供了顯著的發展動力。我們認為公司已做好充分準備，將繼續利用這一動力，進一步參與MENA地區的發展計畫，並在北美地區取得更多市場佔有率。」 2025會計年度第一季業績 截至2025年4月30日的三個月和2024年4月30日的三個月，淨銷售額分別為4670萬美元和3430萬美元。增加的1240萬美元（增幅36%）主要是由於中東和北美的銷售量增加。 截至2025年4月30日的三個月和2024年4月30日的三個月，毛利分別為1670萬美元（占淨銷售額的36%）和1050萬美元（占淨銷售額的31%）。增加的620萬美元主要是由於業務量增加以及產品組合帶來的更高利潤率。 截至2025年4月30日的三個月和2024年4月30日的三個月，一般和行政支出分別為770萬美元和610萬美元。增加的160萬美元是由於本季度薪資支出和專業服務費的增加。 截至2025年4月30日的三個月和2024年4月30日的三個月，銷售支出保持穩定，分別為110萬美元和120萬美元。 截至2025年4月30日的三個月和2024年4月30日的三個月，淨利息支出保持穩定，分別為40萬美元和50萬美元。 截至2025年4月30日的三個月和2024年4月30日的三個月，其他支出保持穩定，均低於10萬美元。 截至2025年4月30日的三個月和2024年4月30日的三個月，公司的有效稅率(ETR)分別為21%和30%。ETR的變動是由於各司法管轄區的盈虧構成不同。 截至2025年4月30日的三個月和2024年4月30日的三個月，歸屬於普通股的淨收入分別為500萬美元和140萬美元。增加的360萬美元主要是由於本季度銷售量增加以及更好的專案執行。 關於Perma-Pipe International Holdings, Inc. Perma-Pipe International Holdings, Inc.（簡稱「公司」）是針對石油和天然氣採集、區域供熱和製冷以及其他應用的預絕緣管道和洩漏偵測系統的全球領導者。公司利用其廣泛的工程和製造專長開發管道解決方案，以解決多種液體安全高效運輸的複雜挑戰。公司總計在六個國家的14個據點經營業務。 前瞻性陳述 本新聞稿中包含的某些陳述和其他資訊可以透過使用前瞻性術語來辨識，構成《1933年證券法》（修訂版）第27A條和《1934年證券交易法》（修訂版）第21E條所定義的「前瞻性陳述」，並受到其中包含的安全港條款的約束，包括但不限於有關公司未來預期業績和營運的陳述。這些陳述應被視為受到公司營運和業務環境中存在的許多風險和不確定性的影響。這些風險和不確定因素包括但不限於以下內容：(i)石油和天然氣價格的波動及其對公司產品客戶訂單量的影響；(ii)公司以優惠價格購買原物料並與供應商保持良好關係的能力；(iii)使用公司產品的政府專案支出減少，以及公司的非政府客戶在流動性和獲得資本資金方面面臨挑戰；(iv)公司償還債務和續延即將到期的國際信貸便利的能力；(v)公司有效執行策略計畫以及實現持續盈利和正現金流的能力；(vi)公司收取與中東專案有關的長期應收帳款的能力；(vii)公司解讀稅收法規和立法變化的能力；(viii)公司利用其淨經營虧損結轉的能力；(ix)由於公司在「超時」確認收入時估計不準確，導致以前記錄的收入和利潤逆轉；(x)公司未能建立和維護有效的財務報告內部控制；(xi)公司產品的訂單接收、執行、交付和驗收時間；(xii)公司就大額合約的進度帳單安排進行成功談判的能力；(xiii)現有競爭對手的激進定價以及新競爭對手進入公司經營的市場；(xiv)公司製造無潛在缺失產品的能力，以及向可能為公司提供有缺失材料的供應商追償的能力；(xv)公司未完成訂單中訂單的減少或取消；(xvi)公司國際業務營運特有的風險和不確定性；(xvii)公司吸引和留住高階管理人員和關鍵員工的能力；(xviii)公司實現成長計畫預期效益的能力；(xix)流行病和其他公共衛生危機對公司及其營運的影響；以及(xx)網路安全威脅對公司資訊技術系統的影響。請股東、潛在投資人和其他讀者在評估前瞻性陳述時仔細考量這些因素，並注意不要過分依賴此類前瞻性陳述。此處所做的前瞻性陳述僅反映本新聞稿發表之日的情況。無論是由於新資訊、未來事件還是其他原因，我們概不承擔公開更新任何前瞻性陳述的義務。有關可能影響我們業績的因素的更多詳細資訊，請參閱我們向美國證券交易委員會遞交的文件，這些文件可在 以及我們網站的「投資人中心」(Investor Center)部分( 公司財政年度截止日為每年1月31日。本報告所述2025年、2024年及2023年財務資料，分別對應截至2026年1月31日、2025年1月31日及2024年1月31日止的財務年度。 有關公司截至2025年1月31日財政年度財務業績的更多資訊，包括管理層對公司財務狀況和經營成果的討論與分析，載於公司截至2025年1月31日的10-Q表年報，這些資料將於本報告發表之日或前後遞交給美國證券交易委員會，並可透過 和 查閱。如欲瞭解更多資訊，請造訪公司網站。 PERMA-PIPE INTERNATIONAL HOLDINGS, INC.及子公司 簡明合併資產負債表 （以千為單位） （未經稽核） 2025年4月30日 2025年1月31日 資產 流動資產 $ 120,700 $ 108,802 長期資產 57,615 56,439 資產總額 $ 178,315 $ 165,241 負債與股東權益 流動負債 $ 61,751 $ 54,063 長期負債 26,459 28,073 負債總額 88,210 82,136 非控制權益 12,238 10,967 股東權益 77,867 72,138 負債和權益總額 $ 178,315 $ 165,241 Expand 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
